Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Gossamer Bio, Inc.
GOSS
$2.46
Name : Gossamer Bio, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $562,702,976.00
EPSttm : -0.61
finviz dynamic chart for GOSS
Gossamer Bio, Inc.
$2.46
1.66%
$0.0415

Float Short %

13.23

Margin Of Safety %

Put/Call OI Ratio

0.09

EPS Next Q Diff

-0.01

EPS Last/This Y

-0.44

EPS This/Next Y

0.18

Price

2.51

Target Price

9

Analyst Recom

1.25

Performance Q

83.82

Relative Volume

0.72

Beta

1.86

Ticker: GOSS




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-09-08GOSS2.640.060.1386253
2025-09-09GOSS2.770.060.0086669
2025-09-10GOSS3.110.070.0287948
2025-09-11GOSS3.450.070.0192257
2025-09-12GOSS3.460.060.02111005
2025-09-15GOSS3.170.060.06111703
2025-09-16GOSS3.20.060.12115636
2025-09-17GOSS2.990.0666423039840760.12110820814283137183
2025-09-18GOSS3.080.070.00155796
2025-09-22GOSS3.150.080.04141952
2025-09-23GOSS3.080.080.06143383
2025-09-24GOSS2.980.080.11143670
2025-09-25GOSS2.790.080.08143669
2025-09-26GOSS2.680.080.00143929
2025-09-29GOSS2.820.080.03142309
2025-09-30GOSS2.620.080.22144387
2025-10-01GOSS2.480.080.02144692
2025-10-02GOSS2.480.080.01145201
2025-10-03GOSS2.570.082.26144793
2025-10-06GOSS2.40.090.03146629
2025-10-07GOSS2.510.092.31147112
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-09-08GOSS2.66-35.788.7-0.68
2025-09-09GOSS2.77-35.782.3-0.68
2025-09-10GOSS3.11-35.778.3-0.68
2025-09-11GOSS3.46-35.778.7-0.68
2025-09-12GOSS3.46-35.784.2-0.68
2025-09-15GOSS3.17-35.7109.3-0.68
2025-09-16GOSS3.20-35.7107.1-0.68
2025-09-17GOSS3.00-35.7108.8-0.68
2025-09-18GOSS3.08-35.7106.6-0.68
2025-09-19GOSS3.05-35.7107.6-0.68
2025-09-22GOSS3.16-35.7106.4-0.68
2025-09-23GOSS3.08-35.7108.0-0.68
2025-09-24GOSS2.98-35.7108.1-0.68
2025-09-25GOSS2.78-35.7109.0-0.68
2025-09-26GOSS2.70-35.7108.0-0.68
2025-09-29GOSS2.82-35.7106.3-0.68
2025-09-30GOSS2.63-35.7108.9-0.69
2025-10-01GOSS2.48-35.7108.6-0.69
2025-10-02GOSS2.46-35.7107.6-0.69
2025-10-03GOSS2.57-35.7106.5-0.69
2025-10-06GOSS2.41-37.5108.0-0.69
2025-10-07GOSS2.51-37.5106.3-0.69
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1




22 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-09-08GOSS0.065.4311.22
2025-09-09GOSS0.065.4311.22
2025-09-10GOSS0.065.4311.22
2025-09-11GOSS0.065.4312.07
2025-09-12GOSS0.065.4312.07
2025-09-15GOSS0.065.4012.07
2025-09-16GOSS0.065.4012.07
2025-09-17GOSS0.065.4012.07
2025-09-18GOSS0.065.4012.07
2025-09-19GOSS0.065.4012.07
2025-09-22GOSS0.065.4112.07
2025-09-23GOSS0.065.4112.07
2025-09-24GOSS0.065.4112.07
2025-09-25GOSS0.065.4113.13
2025-09-26GOSS0.065.4113.13
2025-09-29GOSS0.065.3313.13
2025-09-30GOSS0.065.3313.13
2025-10-01GOSS0.065.3313.13
2025-10-02GOSS0.065.3313.13
2025-10-03GOSS0.065.3313.13
2025-10-06GOSS0.063.5113.13
2025-10-07GOSS0.063.5113.23
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
22 items Current Page1 of 1

Last Quarter Act. EPS

-0.17

Avg. EPS Est. Current Quarter

-0.19

Avg. EPS Est. Next Quarter

-0.18

Insider Transactions

0.06

Institutional Transactions

3.51

Beta

1.86

Average Sales Estimate Current Quarter

6

Average Sales Estimate Next Quarter

9

Fair Value

Quality Score

9

Growth Score

24

Sentiment Score

43

Actual DrawDown %

83.5

Max Drawdown 5-Year %

-96.8

Target Price

9

P/E

Forward P/E

PEG

P/S

14.13

P/B

P/Free Cash Flow

EPS

-0.61

Average EPS Est. Cur. Y​

-0.69

EPS Next Y. (Est.)

-0.51

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-344.81

Relative Volume

0.72

Return on Equity vs Sector %

275.7

Return on Equity vs Industry %

289.4

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

106.3
Gossamer Bio, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 144
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
stock quote shares GOSS – Gossamer Bio, Inc. Stock Price stock today
news today GOSS – Gossamer Bio, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch GOSS – Gossamer Bio, Inc. yahoo finance google finance
stock history GOSS – Gossamer Bio, Inc. invest stock market
stock prices GOSS premarket after hours
ticker GOSS fair value insiders trading